[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-350835-105":59,"doc-detail-350835-en":122},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":115,"head_meta":117,"extra_data":119,"updated_unix":121},105,"en","utility-of-urinary-extracellular-vesicles-for-colorectal-cancer-comparison-of-dna-quality-and-mrd-detection","Utility of Urinary Extracellular Vesicles for Colorectal Cancer - Comparison of DNA Quality and MRD Detection","","This study evaluated the feasibility of urinary extracellular vesicles as a liquid biopsy source for colorectal cancer (CRC) using two predefined cohorts: 97 patients for analytical validation and 63 patients for postoperative survival analysis. Urinary EVs were compared with urinary cell-free tumor DNA, plasma EVs, and plasma ctDNA across multiple molecular dimensions, including proteomic profiling, DNA integrity, and mutation detection sensitivity. Urinary EV-DNA enabled MRD positivity, defined by RAS/BRAF mutations 1 month after curative surgery, strongly linked to recurrence and worse overall survival, supporting urinary EVs as a highly pure, non-invasive tool for postoperative monitoring and risk stratification.",{"@graph":69,"@context":114},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/utility-of-urinary-extracellular-vesicles-for-colorectal-cancer-comparison-of-dna-quality-and-mrd-detection/350835/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/utility-of-urinary-extracellular-vesicles-for-colorectal-cancer-comparison-of-dna-quality-and-mrd-detection/350835.png","ImageObject",300,407,{"name":92,"@type":93},"moss~","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-09","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108],{"name":109,"@type":110,"acceptedAnswer":111},"How was MRD positivity defined, and what was its clinical significance?","Question",{"text":112,"@type":113},"MRD positivity was defined as detectable RAS/BRAF mutations in urinary EV-DNA one month after curative surgery. MRD-positive patients had significantly worse recurrence outcomes and overall survival.","Answer","https://schema.org",{"og:url":83,"og:type":116,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":118,"canonical":83},"index,follow",{"doc_id":120,"site_id":62},350835,1790118906,{"code":4,"msg":5,"data":123},{"doc_id":120,"user_id":124,"nickname":92,"user_avatar":125,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":126,"file_id":127,"file_url":128,"file_type":129,"file_size":130,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":131,"language":132,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":133,"faqs":134,"seo_title":135,"seo_description":67,"update_tm":136,"read_time":137,"preview_page_count":19,"preview_urls":138},962090895452,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Cancer Science  \nORIGINAL ARTICLE  OPEN ACCESS   \nClinical Research  \nUtility of Urinary Extracellular Vesicles for Colorectal Cancer: Comparison of DNA Quality and MRD Detection  \nShintaro Kanaka1  | Takeshi Yamada1  | Fumi Asai2 | Yuta Shimizu2 | Kay Uehara1 | Akihisa Matsuda1 | Seiichi Shinji1  | Yasuyuki Yokoyama1 | Goro Takahashi1 | Takuma Iwai1 | Kohki Takeda1  | Sho Kuriyama1 | Toshimitsu Miyasaka1  | Koki Hayashi1 | Hiroshi Yoshida1  \n1Department of Gastroenterological Surgery, Nippon Medical School, Tokyo, Japan | 2H.U. Group Research Institute, G. K., Tokyo, Japan Correspondence: Takeshi Yamada ([y-tak@nms.ac.jp](y-tak@nms.ac.jp))  \nReceived: 6 December 2025 | Revised: 26 February 2026 | Accepted: 9 March 2026  \nKeywords: colorectal cancer | extracellular vesicle | liquid biopsy | minimal residual disease | urine  \nABSTRACT  \nThis study evaluated the feasibility of urinary extracellular vesicles (EVs) as a liquid biopsy source for colorectal cancer (CRC) using two predefined cohorts: 97 patients for analytical validation and 63 patients for postoperative survival analysis. We compared urinary EVs, urinary cell-free tumor DNA (ctDNA), plasma EVs, and plasma ctDNA across multiple molecular dimensions, and assessed the utility of urinary EV-DNA for minimal residual disease (MRD) detection. Urinary EVs exhibited larger particle size (median 175.6 nm) and markedly higher purity, demonstrated by a substantially broader proteomic profile (4674 vs. 476 proteins) and significantly higher expression of EV-specific markers (CD63, CD81, CD9) . DNA extracted from urinary EVs showed the highest concentration and best preservation of nucleic acid integrity, with the greatest Long/Short fragment ratio, outperforming all plasma-derived samples. Mutation detection sensitivity was comparable across sample types but was highest in plasma ctDNA (39.2%) and urinary EV-DNA (34.0%), exceeding urinary ctDNA (21.6%) . In the survival cohort, MRD positivity—defined as detectable RAS/BRAF mutations in urinary EV-DNA 1 month after curative surgery—was strongly associated with inferior outcomes (HR for recurrence 5.25, 95% CI 1.74–15.80), and overall survival was significantly worse in MRDpositive patients. These findings indicate that urinary EVs provide highly pure vesicles with superior DNA quality, making thema robust and completely non-invasive source for molecular profiling. Urinary EV-DNA–based MRD assessment shows significant prognostic value and may serve as a practical tool for postoperative monitoring and risk stratification in colorectal cancer.  \n1 | Introduction  \nColorectal cancer (CRC) is one of the most common malignancies worldwide, and reliable biomarkers for early detection and postoperative monitoring remain essential for improving clinical outcomes. Liquid biopsy using plasma cell-free tumor DNA (ctDNA) has been well established for assessing tumor burden, treatment response, and minimal residual disease (MRD) [1, 2] . However, several alternative biofluids and analytes—including urine [3], extracellular vesicles (EVs) [4], and circulating tumor  \ncells [5]—have recently gained attention as complementary sources of tumor-derived molecular information.  \nEVs, particularly small EVs, encapsulate DNA, RNA, and proteins within a lipid bilayer that protects their cargo from enzymatic degradation, offering a more stable analyte than free-circulating nucleic acids [6–9] . Importantly, EVs provide a more stable platform for biomarker preservation compared to free-circulating nucleic acids, as their membranous structure protects the internal contents from enzymatic  \n\n| Abbreviations: CRC, colorectal cancer; ctDNA, cell-free tumor DNA; EVs, extracellular vesicles; IRB, Institutional Review Board; MRD, minimal residual disease; NTA, nanoparticle tracking analysis; PBS, phosphate-buffered saline. |\n| --- |\n| This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, dist","cbCaiepk167V3jQu","https://ap.wps.com/l/cbCaiepk167V3jQu","pdf",1204563,11,"English","# Abstract\n# Introduction\n# Material and Methods\n## Patients and Outcome","[{\"question\":\"How was MRD positivity defined, and what was its clinical significance?\",\"answer\":\"MRD positivity was defined as detectable RAS/BRAF mutations in urinary EV-DNA one month after curative surgery. MRD-positive patients had significantly worse recurrence outcomes and overall survival.\"}]","Utility of Urinary Extracellular Vesicles for Colorectal Cancer - Comparison of DNA Quality and MRD Detection | PDF",1790091377,28,[139,143,147,151],{"page_no":8,"url":140,"width":141,"height":142},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/99cde47a5945ee20259bb2d179b96616.webp",983,1291,{"page_no":14,"url":144,"width":145,"height":146},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bfa39cee7c6212186cb26f0ae412500e.webp",982,1290,{"page_no":81,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/71f5a8cfdb2ed47a69946c591fcae515.webp",981,1289,{"page_no":19,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/77be7cafa3accd45e250f210e188cd78.webp",980,1287]